Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Assets:        
Cash and cash equivalents $ 57,427 $ 93,561    
Accounts receivable, net of allowance for credit losses of $41 and $764 as of March 31, 2023 and December 31, 2022, respectively 2,836 4,754    
Contract assets, net 5,383 6,763    
Inventory 28,576 24,133    
Prepaid expenses and other current assets 10,068 9,710    
Total current assets 104,290 138,921    
Property, plant, and equipment, net 31,192 24,743    
Other assets 21,327 18,990    
Total assets 156,809 182,654    
Liabilities and shareholders' deficit:        
Current portion of long-term debt 9,815 7,739    
Accounts payable 26,357 21,188    
Contract liabilities 19,191 27,228    
Reserve for anticipated losses on contracts 1,137 2,860    
Accrued expenses and other current liabilities 16,642 11,721    
Total current liabilities 73,142 70,736    
Long-term debt 148,042 142,620    
Warrant and derivative liabilities 49,405 39,950    
Other liabilities 21,545 20,769    
Total liabilities 292,134 274,075    
Commitments and contingencies (Note 12)    
Shareholders' deficit:        
Preferred stock - authorized 50,000,000 shares of $0.0001 par value as of March 31, 2023 and December 31, 2022; zero issued and outstanding    
Common stock - authorized 300,000,000 shares of $0.0001 par value as of March 31, 2023 and December 31, 2022; issued and outstanding shares of 144,680,223 and 142,503,771 as of March 31, 2023 and December 31, 2022, respectively 14 14    
Additional paid-in capital 280,095 269,574    
Accumulated deficit (415,613) (361,168)    
Accumulated other comprehensive income 179 159    
Total shareholders' deficit (135,325) (91,421)   $ (99,357)
Total liabilities and shareholders' deficit $ 156,809 $ 182,654